These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2617427)

  • 1. [Drug information. New bismuth preparation against presumed cause of gastric ulcer].
    Dahlerup J
    Sygeplejersken; 1989 Nov; 89(46):14-5. PubMed ID: 2617427
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence].
    Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D
    Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ulcer--campylobacter pylori--bismuth therapy].
    Internist (Berl); 1989 Feb; 30(2 Suppl [ULKUS]):1-11. PubMed ID: 2635701
    [No Abstract]   [Full Text] [Related]  

  • 5. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
    Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA
    Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].
    Maev IV; Samsonov AA; Golubev NN
    Klin Med (Mosk); 2008; 86(9):57-63. PubMed ID: 19048841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat.
    Koo J; Ho J; Lam SK; Wong J; Ong GB
    Gastroenterology; 1982 May; 82(5 Pt 1):864-70. PubMed ID: 7060908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled trial comparing colloidal bismuth subcitrate tablets, cimetidine and placebo in the treatment of gastric ulceration.
    Tytgat GN; van Bentem N; van Olffen G; Dekker W; Rutgeerts L; de Boer J
    Scand J Gastroenterol Suppl; 1982; 80():31-8. PubMed ID: 6761850
    [No Abstract]   [Full Text] [Related]  

  • 10. [A comparison of tripotassium dicitratobismuthate and cimetidine in the treatment of gastric ulcer].
    Chen SP; Pan GZ
    Zhonghua Nei Ke Za Zhi; 1986 Aug; 25(8):456-7, 509. PubMed ID: 3803058
    [No Abstract]   [Full Text] [Related]  

  • 11. Present and future treatment of peptic ulcer and potential role of DE-NOL.
    Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
    [No Abstract]   [Full Text] [Related]  

  • 12. [Search for the best procedure for Campylobacter eradication. Results of long-term studies are still unavailable].
    Börsch G
    Fortschr Med; 1989 Jul; 107(22):471-2. PubMed ID: 2793022
    [No Abstract]   [Full Text] [Related]  

  • 13. Colloidal bismuth subcitrate.
    Simjee AE
    S Afr Med J; 1988 Jul; 74 Suppl():61-3. PubMed ID: 3291158
    [No Abstract]   [Full Text] [Related]  

  • 14. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?].
    Menge H
    Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ulcer disease--drug treatment and its limitations].
    Arnold R
    Chirurg; 1990 Jan; 61(1):1-9. PubMed ID: 2107066
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacokinetics of bismuth preparations in patients with gastritis and ulcer disease].
    Raedsch R; Walter-Sack I; Weber E; Blessing J
    Klin Wochenschr; 1990 May; 68(9):488. PubMed ID: 2355728
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate.
    Andrews PC; Deacon GB; Forsyth CM; Junk PC; Kumar I; Maguire M
    Angew Chem Int Ed Engl; 2006 Aug; 45(34):5638-42. PubMed ID: 16865763
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with Campylobacter pylori in western Kentucky.
    Kraus JW; Morello PJ
    J Ky Med Assoc; 1989 Sep; 87(9):448-50. PubMed ID: 2794757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.